Sign in or create an account to add this stock to your watchlist.
About Evolus (NASDAQ:EOLS)
Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EOLS
CUSIPN/A
Phone949-284-4555
Debt
Debt-to-Equity RatioN/A
Current Ratio13.84
Quick Ratio13.84
Price-To-Earnings
Trailing P/E Ratio-83.11
Forward P/E Ratio-13.60
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.20 per share
Price / Book10.20
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees21
Outstanding Shares23,640,000
Evolus (NASDAQ:EOLS) Frequently Asked Questions
What is Evolus' stock symbol?
Evolus trades on the NASDAQ under the ticker symbol "EOLS."
How were Evolus' earnings last quarter?
Evolus (NASDAQ:EOLS) posted its quarterly earnings data on Thursday, May, 10th. The company reported ($0.30) EPS for the quarter, topping the Zacks' consensus estimate of ($0.36) by $0.06. View Evolus' Earnings History.
What price target have analysts set for EOLS?
4 Wall Street analysts have issued 1-year target prices for Evolus' shares. Their forecasts range from $20.00 to $25.00. On average, they expect Evolus' share price to reach $22.50 in the next year. View Analyst Ratings for Evolus.
What are Wall Street analysts saying about Evolus stock?
Here are some recent quotes from research analysts about Evolus stock:
- 1. Mizuho analysts commented, "We lowered our estimates and pushed out the forecast (U.S. launch in 3Q:19 vs. 1Q:19 previously), driving a PT reduction to $16 from $21. Reiterate Buy." (5/16/2018)
- 2. According to Zacks Investment Research, "Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. " (5/15/2018)
- 3. Cantor Fitzgerald analysts commented, "We spoke with an aesthetic dermatologist today to get his views on how the potential approval of less expensive and/or longer acting toxins could change the existing market. Based on our discussion, we see an opportunity for new toxins such as EOLS’s (OW) DWP-450 and RVNC’s (OW) RT002 to take meaningful market share for AGN’s (N) Botox as well as grow the entire market." (4/25/2018)
Are investors shorting Evolus?
Evolus saw a increase in short interest in May. As of May 15th, there was short interest totalling 1,021,392 shares, an increase of 45.4% from the April 30th total of 702,692 shares. Based on an average daily trading volume, of 358,943 shares, the short-interest ratio is currently 2.8 days. Approximately 20.6% of the company's stock are sold short.
Who are some of Evolus' key competitors?
Some companies that are related to Evolus include Insmed (INSM), Intercept Pharmaceuticals (ICPT), OPKO Health (OPK), Akcea Therapeutics (AKCA), Puma Biotechnology (PBYI), Spectrum Pharmaceuticals (SPPI), Aimmune Therapeutics (AIMT), Enanta Pharmaceuticals (ENTA), Prestige Brands (PBH), AnaptysBio (ANAB), Phibro Animal Health (PAHC), Akorn (AKRX), MyoKardia (MYOK), G1 Therapeutics (GTHX) and Madrigal Pharmaceuticals (MDGL).
Who are Evolus' key executives?
Evolus' management team includes the folowing people:
- Mr. Murthy V. Simhambhatla Ph.D., Pres, CEO & Director (Age 52)
- Mr. Kris Garcia, VP of Fin.
- Dr. J. Christopher Marmo Ph.D., Chief Operating Officer (Age 49)
- Jeffrey J. Plumer, VP of Legal
- Ms. September Riharb, VP of Marketing
When did Evolus IPO?
(EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.
Has Evolus been receiving favorable news coverage?
News articles about EOLS stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Evolus earned a media sentiment score of 0.13 on Accern's scale. They also gave media stories about the company an impact score of 43.79 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Evolus' major shareholders?
Evolus' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.80%), Citadel Advisors LLC (0.73%), Landscape Capital Management L.L.C. (0.30%), Northern Trust Corp (0.24%), Dean Capital Investments Management LLC (0.15%) and California Public Employees Retirement System (0.14%). View Institutional Ownership Trends for Evolus.
Which major investors are buying Evolus stock?
EOLS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Citadel Advisors LLC, Landscape Capital Management L.L.C., Northern Trust Corp, Dean Capital Investments Management LLC, California Public Employees Retirement System and Mizuho Securities USA LLC. View Insider Buying and Selling for Evolus.
How do I buy shares of Evolus?
Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Evolus' stock price today?
One share of EOLS stock can currently be purchased for approximately $22.44.
How big of a company is Evolus?
Evolus has a market capitalization of $530.48 million. The company earns $-4,480,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Evolus employs 21 workers across the globe.
How can I contact Evolus?
Evolus' mailing address is 17901 Von Karman Avenue Suite 150, Irvine CA, 92614. The company can be reached via phone at 949-284-4555 or via email at [email protected]
MarketBeat Community Rating for Evolus (EOLS)
MarketBeat's community ratings are surveys of what our community members think about Evolus and other stocks. Vote "Outperform" if you believe EOLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EOLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Evolus (NASDAQ:EOLS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Evolus in the last 12 months. Their average twelve-month price target is $22.50, suggesting that the stock has a possible upside of 0.27%. The high price target for EOLS is $25.00 and the low price target for EOLS is $20.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | N/A | N/A |
| Consensus Rating Score: | 3.00 | 3.00 | N/A | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $22.50 | $22.50 | N/A | N/A |
| Price Target Upside: | 0.27% upside | 185.90% upside | N/A | N/A |
Evolus (NASDAQ:EOLS) Consensus Price Target History
Evolus (NASDAQ:EOLS) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Evolus (NASDAQ:EOLS) Earnings History and Estimates Chart
Evolus (NASDAQ:EOLS) Earnings Estimates
2018 EPS Consensus Estimate: ($1.61)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2018 | 1 | ($0.36) | ($0.36) | ($0.36) |
| Q2 2018 | 1 | ($0.37) | ($0.37) | ($0.37) |
| Q3 2018 | 1 | ($0.45) | ($0.45) | ($0.45) |
| Q4 2018 | 1 | ($0.43) | ($0.43) | ($0.43) |
Evolus (NASDAQ EOLS) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2018 | Q1 2018 | ($0.36) | ($0.30) | | | View | N/A |  |
| 3/29/2018 | Q4 2017 | | $0.24 | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Evolus (NASDAQ:EOLS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Evolus (NASDAQ EOLS) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 18.80%
Evolus (NASDAQ EOLS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Evolus (NASDAQ EOLS) News Headlines
| Source: |
|
Evolus (NASDAQ:EOLS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Evolus (NASDAQ EOLS) Stock Chart for Sunday, May, 27, 2018
Loading chart…
